Clindamycin, cutaneous

Generic name
Clindamycin, cutaneous
Brand name
ATC Code
D10AF01
Compare …

Clindamycin, cutaneous

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Acne vulgaris
  • Cutaneous
    • ≥ 12 years

      • 1%:  Apply a thin layer once or twice daily to the affected skin.

      • Duration of treatment:

        minimum 6 weeks, maximum 3 months

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Retinoids for topical use in acne
D10AD03
D10AD53
D10AD01
Peroxides
D10AE01
Antiinfectives for treatment of acne
D10AF51
D10AF02
D10AF51
Other anti-acne preparations for topical use
D10AX03

References

  1. Pfizer Corporation Austria Ges.m.b.H., Wien, SmPC Dalacin-T (1-20589) , 02-2019
  2. Bruinsma M, et al, NHG Standaard Acne (derde herziening), Huisarts Wet, 2017 (april)
  3. Infectopharm, SmPC Zindaclin 1% Gel (54182.00.00), 01/15
  4. Teva Nederland BV, SmPC Clindamycine oplossing voor cutaan gebruik (RVG 108315) 29-12-2020, www.geneesmiddeleninformatiebank.nl
  5. Infectopharm, SmPC Zindaclin 1% Gel (54182.00.00), 01/15
  6. Pfizer Corporation Austria Ges.m.b.H., Wien, SmPC Dalacin-T (1-20589), 02-2019

Changes

Therapeutic Drug Monitoring


Overdose